SILEX SYSTEMS LIMITED onlyuseSilex Systems Limited
Investor Presentation
personal(ASX: SLX) (OTCQX: SILXY) For
www.silex.com.au1
Forward Looking Statements and Risk Factors
onlyAbout Silex Systems Limited (ASX: SLX) (OTCQX: SILXY)
Silex Systems Limited ABN 69 003 372 067 (Silex or Company) is a research and development company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company's technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee Global Laser Enrichment LLC (GLE) for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors including the satisfactory completion of the engineering scale-up program and uranium market conditions and therefore remains subject to associated risks.
useSilex is also in the early stages of pursuing additional commercial applications of the SILEX technology, including the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing. The 'Zero-Spin Silicon' project remains dependent on the outcomes of the project and the viability of silicon quantum computing and is therefore subject to various risks. The commercial future of the SILEX technology is therefore uncertain and any plans for commercial deployment are speculative.
Additionally, Silex has an interest in a unique semiconductor technology known as 'cREO®' through its 100% ownership of subsidiary Translucent Inc. The cREO® technology developed by Translucent has been acquired by IQE Plc based in
the UK. IQE is developing the cREO® technology towards potential commercial deployment for 5G mobile handset filter applications. The outcome of IQE's commercialisation program is also uncertain and remains subject to various technology personaland market risks.
Forward Looking Statements
The commercial potential of these technologies is currently unknown. Accordingly, no guarantees as to the future performance of these technologies can be made. The nature of the statements in this Presentation regarding the future of the SILEX technology as applied to uranium enrichment and Zero-Spin Silicon production, the cREO® technology and any associated commercial prospects are forward-looking and are subject to a number of variables, including but not limited to, unknown risks, contingencies and assumptions which may be beyond the control of Silex, its directors and management. You are strongly cautioned not to place reliance on any forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by COVID-19 and other economic risk factors, as actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors. Further, the forward-looking statements contained in this Presentation involve subjective judgement and analysis and are subject to change due to management's analysis of Silex's business, changes in industry trends, government policies and any new or unforeseen circumstances. The Company's management believes that there are reasonable grounds to make such statements as at the date of this Presentation. Actual operations, results,
erformance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.
Except as required by law or regulation (including the ASX Listing Rules and OTCQX Rules for U.S. Companies), Silex does not intend, and is not obligated, to update the forward-looking statements and Silex disclaims any obligation or undertaking to update forward-looking statements in this Presentation to reflect any changes in expectations.
ForNo representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur.
Risk Factors
Risk factors that could affect future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to the impacts of the COVID-19 pandemic; the results of the SILEX uranium enrichment engineering development program; the market demand for natural uranium and enriched uranium; the outcome of the project for the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing; the potential development of, or competition from alternative technologies; the potential for third party claims against the Company's ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the USA, Australia or elsewhere; results from IQE's commercialisation program and the market demand for cREO® products; decisions made or actions taken by the Company's commercialisation partners that
could adversely affect the technology development programs; and the outcomes of various strategies and projects undertaken by the Company.
Cover page image accreditation: Prof. Michelle Simmons team at UNSW/CQC2T demonstrated the fastest 2 qubit gate in silicon using atom qubits. Nature 571, 371 (2019) (Illustration by Tony Melov). | www.silex.com.au | 2 |
For personal use only
Our Mission: to commercialise the unique SILEX laser
enrichment technology for application to:
Uranium production and | Silicon enrichment (silicon | Other potential markets (e.g. |
enrichment (nuclear power) | quantum computing) | medical isotopes) |
Our strategy is focused on extracting maximum value
from our core SILEX technology and expertise
www.silex.com.au3
For personal use only
Highlights of the last 12 months
SILEX Uranium Enrichment Technology / GLE Highlights:
- GLE acquisition completed January 2021 - resulting in Silex acquiring a 51% interest in GLE (Cameco 49%)
- GLE recruited key executives - CEO and CCO with extensive technical and commercial acumen to lead GLE
- GLE continues to make good progress in the execution of the technology demonstration project and commercialisation strategy
- HALEU fuel opportunity for advanced Small Modular Reactors - emerging as next generation nuclear power reactors
Other highlights:
- Zero-SpinSilicon (ZS-Si) project Stage 2 completed January 2022 - demonstration of ZS-Si production with prototype facility
- Assessment of other applications of the SILEX technology ongoing (focus currently on medical radioisotopes)
- Capital raising completed October 2021, net Placement proceeds ~$31.4 million plus Share Purchase Plan ~$7 million
www.silex.com.au4
For personal use only
Uranium Production and Enrichment for Nuclear Fuel
www.silex.com.au5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Silex Systems Limited published this content on 23 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2022 23:00:42 UTC.
